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Abstract: The experimental evaluation of metastasis overly focuses on the gain of migratory
and invasive properties, while disregarding the contributions of cellular plasticity, extra-cellular
matrix heterogeneity, niche interactions, and tissue architecture. Traditional cell-based assays
often restrict the inclusion of these processes and warrant the implementation of approaches that
provide an enhanced spatiotemporal resolution of the metastatic cascade. Time lapse imaging
represents such an underutilized approach in cancer biology, especially in the context of disease
progression. The inclusion of time lapse microscopy and microfluidic devices in routine assays
has recently discerned several nuances of the metastatic cascade. Our review emphasizes that
a complete comprehension of metastasis in view of evolving ideologies necessitates (i) the use
of appropriate, context-specific assays and understanding their inherent limitations; (ii) cautious
derivation of inferences to avoid erroneous/overestimated clinical extrapolations; (iii) corroboration
between multiple assay outputs to gauge metastatic potential; and (iv) the development of protocols
with improved in situ implications. We further believe that the adoption of improved quantitative
approaches in these assays can generate predictive algorithms that may expedite therapeutic strategies
targeting metastasis via the development of disease relevant model systems. Such approaches
could potentiate the restructuring of the cancer metastasis paradigm through an emphasis on the
development of next-generation real-time assays.
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1. Introduction
Metastasis generates a systemic disease driven by the concerted alliance of tumor cell dissociation,
physical translocation, and distant colonization. The dissociation of cells from the primary tumor
initiates the metastatic cascade and generates distinct entities defined by severance dynamics of cell
adhesion complexes. Further, acquisition of migratory/invasive properties by tumor cells facilitates their
entry into circulation (or lymphatic system), wherein they evade host immune responses and endure
extrinsic pressures followed by extravasation at secondary site(s). Tumor cell dormancy and secondary
site remodeling then define the latency of colonization, which eventually establishes metastatic
lesions [1–3]. An intricate interplay of molecular networks drives these programs and contributes to the
efficacy of tumor progression [1–4]. Phenotypic switches induced by epithelial–mesenchymal transitions
(EMT) are widely studied, and are deemed crucial for successful metastasis. Alternatively, recent studies
highlight a collective mode of dissemination, wherein the retention of several epithelial properties is
well documented [1–4]. These processes are further influenced by numerous physiological parameters,
including the tissue stroma, architecture, and extra-cellular matrix (ECM) composition, in order to
facilitate the successful establishment of a secondary disease [1–4]. Thus, collaboration amongst
diverse functionalities outlines a complex blueprint of the process, wherein distinct modes of tumor
cell dissemination can influence disease aggressiveness and therapeutic response.
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Routine analyses in cancer metastasis studies inadvertently employ endpoint or “snapshot”
assays that widely focus on the physical translocation of cancer cells. Functional read-outs tend to
simplify various aspects of metastasis, and often neglect the role of tumor heterogeneity in disease
progression. Furthermore, current notions extensively associate dissemination with a mesenchymal
phenotype, and disregard the contributions of the alternate processes that are often unnoticed by
existing experimental systems [3,5,6]. Detailed examination of the metastatic cascade thus necessitates
the integration of the recent conceptual and technical advances for the development of informative assay
protocols. In this article, we present a reassessment of the functional read-outs routinely employed in
metastasis-associated studies, and accentuate the application of high-resolution imaging approaches to
derive relevant patho-physiological conclusions.
2. Snapshot Assays for Metastasis Assessment
Reliance on snapshot assays in cancer research is accounted for by several advantages, including the
ease of execution, reproducibility, and applicability in high throughput screens. In vitro functional
read-outs provide a preliminary assessment of the metastatic capabilities, while the variables
contributing to tumor heterogeneity viz., micro-environmental milieu, tissue specific metabolic
gradients, and systemic architecture, are often assessed with in vivo models. While our review
focusses on the widely employed functional assays corresponding to three distinct stages of metastasis,
viz., primary dissociation, physical translocation, and colonization, we briefly discuss the molecular
approaches routinely used in cancer biology (Figure 1).
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Figure 1. Functional assays for the metastatic cascade. Metastasis encompasses three distinct stages,
viz. primary dissociation, physical translocation, and colonization. The interplay of complex processes
severs cells from the primary tumor; these cells proliferate, migrate, and invade through the tissue
matrix to initiate hematogenous or lymphatic dissemination.
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Circulating tumor cells then overcome hydrostatic pressures and immune surveillance to extravasate
and colonize distant tissues to seed micro-/macro-metastases. Diverse cellular functions activated
during the metastatic cascade are evaluated experimentally by functional assays, and can be modified to
accommodate multiple biological components (micro-environmental milieu, extra-cellular matrix–ECM,
stromal cells, extrinsic physical pressures, immune cells, and so on). A list of the relevant assays
employed across the metastatic cascade are listed and indicated in the schematic.
2.1. Molecular Assays
The functional assessment of metastasis is often correlated with the molecular signatures derived
from tumor cells or cell line models. Primary profiling studies employ a wide range of markers
identified across the metastatic cascade, which include cell junction and cytoskeletal components,
transcription factors (TFs), secretory enzymes, and cell surface receptors [7]. Molecular profiles,
averaged from a cell population, can often misrepresent disease heterogeneity, as affirmed by the reports
on single cell characterization, besides over-emphasizing the role of EMT during metastasis [8–10].
Microscopy studies further associate the sub-cellular localization of several phenotype associated
markers and TFs with distinct cellular functions [11,12]. Importantly, recent reports associating altered
marker sub-cellular localization with pathological conditions necessitate the inclusion of this parameter
in clinical assessments [13–15]. Furthermore, mechanistic studies on cell state maintenance employ
fluorescence or enzyme (luciferase, β-galactosidase, and chloramphenicol acetyltransferase) assisted
reporter systems for quantifying gene regulation [16,17]. Apart from the static molecular profiles,
cytoskeletal, vesicular, and membrane dynamics, as captured by microscopy, offer deeper insight into
the alterations of the cell shape and function [18–20].
Molecular assays, however, rely on markers that often exhibit extensive disparities across model
systems, and are subject to cellular context-specific modulation [21–23]. E-cadherin expression
and membrane localization, often gauged in clinical specimens by immuno-histochemical scoring,
were exclusively associated with the lack of metastasis [24–26]; however, the detection of this
adherens junction molecule in collectively metastasizing cells challenges its inverse correlation with
dissemination [27,28]. Recently, E-cadherin negative cells have also been reported to exhibit collective
migration by virtue of CD44 mediated cell-cell adhesion in invasive breast lobular carcinoma [29].
Such discrepancies arise from tissue-specific plasticity programs that are influenced by the local
microenvironment. Similarly, the divergent contribution of regulatory TFs in metastasis has been
reported; some examples include the stage specific roles of the EMT-mediating TFs Zeb1 and Zeb2
in pancreatic cancer and melanoma dissemination [30,31]; an EMT-TF circuitry switch in melanoma,
wherein Slug–Zeb2 act as tumor suppressors in melanocytes, while Twist1–Zeb1 function towards
neoplastic transformation [32]; the tissue-specific expression of the Prrx1 isoforms (Prrx1a and
Prrx1b) that govern the distinct phenotypic states in pancreatic and breast cancer progression [33,34];
the co-operative role of Slug and Sox9 in the maintenance of breast epithelium homeostasis [35];
and so on. Thus, assigning relevance to metastases signatures requires an accompanying physiological
comprehension of the cellular plasticity, and corroboration with tissue specific molecular profiles,
mechanistic approaches, and imaging protocols.
2.2. Functional Assays
The examination of functionalities across the physiological and pathological states is robustly
aided by cell-based assays. Routinely employed assays in cancer biology gauge the properties of
anoikis resistance, stemness, migration, invasion, and colonization, so as to correlate with clinical
observations (Table S1 and Figure 1).
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2.2.1. In Vitro Assays
The loss of cell–cell and cell–matrix contacts initiates the anoikis cascade under physiological
conditions, whereas resistance to this cell-death pathway in tumor cells permits effective disease
progression [36]. The in vitro assessment of “anoikis” relies on the differential uptake of fluorescent dyes
or the biochemical conversions of fluorophores by viable versus non-viable cells. Dissociated tumor
cells exhibit a tendency to generate organized multi-cellular structures termed “spheroids”,
disorganized “cellular aggregates”, or they exist as single cells [37]. Cell aggregates and spheroids exhibit
stem-like and anoikis resistance properties, and are associated with disease aggressiveness [38,39].
The functional attributes of cell migration and invasion are also hijacked during tumor progression.
Routine assessment of migratory capabilities by the “in vitro wound closure assays” is often enhanced
by the fluorescent tagging of cells with reporter proteins or membrane labelling dyes [40,41]. The efficacy
of tumor cell intra-/extra-vasation is recapitulated in vitro by trans-well inserts of pre-defined pore
sizes. Such assays are employed widely to quantify “cell motility” in response to a chemotactic
agent, while the layering of artificial matrix components (such as matrigel, carboxy methyl cellulose,
and hydrogels) over these inserts gauge properties of “cell invasion” and “ECM remodeling” [38].
Recent trans-well systems employ micro-electrode coupled inserts that measure the impedance flux in
response to cell migration/invasion, with enhanced precision [42]. Tumor cell invasion also entails the
biochemical and mechanical modification of ECM components. “ECM degradation assays” measure
the enzymatic activity of secreted matrix metalloproteinases (MMPs) by employing fluorescently
labelled substrates and quantifying the signal intensity in the vicinity of invasive tumor cells [43].
Additional information pertaining to tumor cell invasion is gained from the “co-culture assays” that
recapitulate the in-situ disruption of non-transformed tissue linings often encountered by metastasizing
cancer cells [44]. The use of differentially labelled non-transformed and cancer cells improves the
resolution of this assay, by enhancing the visualization and quantification of monolayer perturbance
and invasion by tumor cells. Monolayer disruption by invading cancer cells is also quantified by
the “trans-epithelial resistance (TER)” and “dextran flux assays” that gauge monolayer integrity and
permeability, respectively [45,46]. Recent developments in advanced microfluidic and flow cytometry
approaches have also facilitated the isolation of “circulating tumor cells (CTCs)”, which are actual
proof of an ongoing metastatic cascade [10,47]. Several recent reviews detail, at length, the role of
CTCs in tumor biology and translational medicine, and associate them with stem-like properties,
immune evasion signatures, and immense phenotypic plasticity [48–50]. CTCs also offer excellent
diagnostic/prognostic value and specific targeting opportunities [51–53]. Hence, their detection,
quantification, and analyses are being developed in view of clinical applications.
Cell-substrate adhesion, governed by tissue specific ECM components, represents a critical
determinant of metastatic seeding [54–56]. The in vitro assessment of “adhesion” employs ECM
pre-coated plates to identify the critical molecular players mediating cell–matrix interactions [57].
Separately, anchorage independent growth of tumor cells as gauged by the “soft agar assay” utilizes
a three-dimensional (3D) matrix devoid of ECM components, and quantifies the tumor seeding capacity
in vitro [58]. Apart from studies pertaining to single cell colonization, spheroids and cell aggregates
are also functionally examined for their properties of adhesion, migration, and invasion, which can be
extrapolated to the metastatic cascade [38]. Furthermore, the competitive interaction of these entities
in suspension is assessed by “spheroid confrontation”; such an assay evaluates the differential invasive
capabilities, as well as co-operation between these cell populations in view of metastases seeding [38].
Despite their obvious advantages, cell line models provide limited information on the in
situ landscape of a disease, because of a lack of higher order organization conferred by the
tissue architecture. “Organoid cultures” represent an in vitro 3D model system reminiscent of
the in-situ organization, and provide improved clinical correlations [59]. The sustenance of genetic
features from patient samples by organoids make them improved models for studying metastases
as opposed to cell lines, which can often accumulate genetic aberrations over multiple passages [60].
Their amenability to in vitro functional assays further permits a high throughput assessment of
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pathological states. Studies with pancreatic and colorectal cancer organoids, established from clinical
specimens, demonstrate the recapitulation of histological features reminiscent of the parental tissue,
when injected into immunocompromised mice [61,62]. Interestingly, stage-specific organoids have
also captured the evolving heterogeneity and molecular landscapes of tumors, and can improve the
efficacy of therapeutic interventions in personalized medicine [63]. Similarly, organoids have been
developed from CTCs that exhibit drug-resistance responses similar to the patients, and are amenable to
high-throughput screening for the design of personalized therapeutic regimes [64]. Additional details
on the advancements in organoid generation and utility in cancer biology are stated elsewhere [64–66].
2.2.2. In Vivo Systems
Despite the widespread applicability of in vitro systems, several aspects of metastasis that
contribute to its complexity and heterogeneity are comprehended only when examined in vivo.
Several non-mammalian systems have been extensively studied so as to comprehend the functionalities
associated with the metastatic cascade. Examples include chemotactic migration observed
in Dictyostelium discoideum, anchor cell invasion documented during vulva morphogenesis in
Caenorrhabditis elegans, collective cell migration of ovarian border cells in Drosophila melanogaster, and the
amoeboid migratory phenotype associated with primordial germ cells of Danio rerio. Extensive details
on these non-mammalian models have been documented elsewhere [67]. Similarly, the developing
chick embryo has been utilized for the assessment of its metastatic capabilities. The traditional chick
“chorioallantoic membrane” assay quantifies tumor cell invasion across embryonic layers, and is
assessed microscopically [68,69]. Recent “ex ovo embryo-xenograft models”, however, serve as
improved visual and quantitative systems for metastatic dissemination and intra-vital imaging [69].
Despite the evolutionary divergence, the conservation of distinct cellular functionalities in these animal
models, along with their amenability to genetic screens and live cell imaging, permit the extrapolation
of relevant observations to mammalian systems. However, the routine and widespread utility of mouse
models in cancer biology as opposed to non-mammalian systems continues, because of emphasis on
the clinically relevant settings that are more effectively mimicked by genetically engineered mice.
“Mouse models” recapitulate physiological variables contributing to disease progression, which are
absent in vitro and allow for the derivation of clinically relevant outputs. We describe briefly
a few mouse models and assays employed in tumor biology; interested readers may refer to other
detailed articles [70–72]. The metastatic cascade is routinely captured by spontaneous models for
metastasis that involves ectopic/orthotopic tumor cell transplantation in immunocompromised mice.
Orthotopic models more effectively represent disease progression, as they expose tumor cells to the
micro-environmental cues encountered in the tissue of origin. Alternatively, experimental models
of metastasis include the inoculation of tumor cells into mice so as to assess the property of distant
colonization. Intra-cardiac, intra-peritoneal, intra-splenic, the tail vein, and so on, are known routes of
tumor cell injection, and have been documented to govern the tissue specificity of metastatic seeding [72].
Recent advances in bioluminescent imaging also permits the non-invasive detection of metastatic
seeding by tagged tumor cells, thus ensuring real-time assessment [17,73]. These mouse models include
cell-line generated allograft or xenograft systems that often lack the stromal/immune cell heterogeneity
associated with the disease; the development of carcinogen-induced and genetically engineered mouse
models has allowed cancer biologists to overcome this drawback. 7,12-Dimethylbenz[a]anthracene
and azoxymethane-induced skin squamous cell and colorectal carcinoma mouse models, respectively,
have been employed in deciphering the mechanisms of carcinogen mediated disease progression [74,75].
Cell lineage specific disease models, generated by Cre-lox approaches, have identified the molecular and
cellular cascades contributing to metastasis and discerned disease associated patterns across stochastic
cellular events [76,77]. For the improved recapitulation of breast cancer in mice, the mammary fat
pad model system was developed so as to ensure the repopulation and manipulation of the mouse
mammary gland with human-derived epithelia [78]. Similarly, patient-derived xenografts (PDXs)
have been established, which can recapitulate metastatic and organ homing properties similar to
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the clinical specimen [79]. Fluorescent tagging of lineage-specific tumor cells and the establishment
of confetti mouse models permits the tracing, isolation, and characterization of cell populations,
thereby systematically dissecting the events involved in development and disease progression [80–83].
Reporter tags also facilitate CTC isolation and the detection of low frequency tumor cells at secondary
sites during the colonization phase of metastasis [79]. Similarly, inducible reporter systems permit the
fine tuning of specific molecular events, besides contributing to the spatiotemporal resolution of gene
regulatory networks driving metastasis [75].
Functional assays and model systems thus simplify the comprehension of several mechanisms
contributing to metastasis. However, the stromal and immune cell populations that facilitate metastasis
are often under-represented in classical assays. These cellular interactions include platelet-coated
CTCs, which exhibit enhanced survival and immune evasion; cancer associated fibroblasts (CAFs)
or tumor associated macrophages (TAMs) in the primary and metastasizing tumor, which facilitate
the generation of a supportive niche; and so on. [2,84,85]. Furthermore, the information provided by
each assay exhibits cell-type and experimental-system associated context dependency [86]. Hence,
an acknowledgement of the inherent shortcomings for each methodology is crucial, prior to the
derivation of relevant conclusions, and may necessitate the development of improved protocols.
2.3. Scrutinizing Outcomes of Metastasis Assays
Most conventional in vitro assays associate metastasis with migratory and invasive capacities,
while the processes of cell dissociation and colonization remain under-represented. Isolated read-outs
can misrepresent the metastatic cascade and hinder effective translation of in vitro observations.
Herein, we summarize the relevant biological limitations associated with in vitro read-outs (Table S2),
and emphasize that a routine re-evaluation of assays is necessary for deriving appropriate
clinical inferences.
The effective dissociation of cells from the primary tumor generates varied metastasizing
entities (heterogeneous cell aggregates, single mesenchymal cells, and epithelial cell clusters) based
on their modes of severance [37,87,88]. Differential molecular programs activated during cell
dissociation from the primary tumor endow cells with functional signatures that can influence
assay read-outs (Figure 2a). The acquisition of anoikis resistance by these entities is influenced by
membrane dynamics, modified secretome, immune/stromal cell recruitment, and forces generated by
primary tissue/interstitial fluids; parameters that are often neglected by in vitro assays [36,89,90].
Similar influences also distinguish cell aggregates from spheroids, and demand unambiguous
identification approaches for these suspension entities [37]. The re-organization of tissue architecture
during metastasis further employs processes that can degrade and/or realign specific ECM components
in order to ensure optimal dissemination and colonization (Figure 2b.i) [91–93]. While ECM-based
assays discern the molecular players of cell adhesion and degradation, there is limited comprehension
of the influences from 3D-ECM rearrangement. For example, with minimal biochemical changes,
collagens can undergo rearrangement with respect to fiber density and crosslinking, so as to alter
cell–ECM interactions [94]. Similarly, degradation assays more commonly quantify the biochemical
aspect of cell–ECM interaction, while the mechanical forces that can distort ECM arrangement are
largely ignored (Figure 2b.ii) [43,95,96]. Existing assays also disregard the amoeboid mode of invasion,
wherein cells exhibit a greater degree of deformability, which facilitates displacement across the ECM
with minimal biochemical or mechanical alterations of the matrix [97,98].
In vitro migration and invasion assays present with similar shortcomings, wherein the
heterogeneity and mechanics of these processes are excessively simplified and the modalities of
translocation are overlooked. Wound closure assays widely imply cell migration, while disregarding
the proliferative potential of the wound edge [99]. Similarly, experimental systems often employ
scratch and gap closure assays interchangeably, with a complete disregard for the differential biological
annotations represented by each method. While “gaps” (cell-free zones) are passively generated by
artificial barriers positioned around proliferating cells, scratch assays involve the active disruption
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of cell monolayers. These differences can influence the activation of differential molecular networks
and affect assay outputs [40,41]. Furthermore, trans-well assays restrict the movement of collectively
invading cells, because of the pre-defined insert pore size that usually permits the passage of single
cells. Similarly, co-culture systems often do not account for the paracrine effects of invading tumor cells
on the epithelial/endothelial monolayers; these can activate the trans-differentiation and chemotaxis
programs involved in the recruitment of CAFs, TAMs, and so on [84,85]. Most read-outs for migration
and invasion also assume an onset of EMT, while the contributions of extra-tumoral cells recruited
for their cooperative effects are often disregarded (Figure 2b.ii) [100]. Similarly, the plasticity of
migratory/invasive modalities in response to differential ECM density, composition, and arrangement
also requires critical scrutiny [101].
J. Clin. Med. 2019, 8, x FOR PEER REVIEW 7 of 22 
 
 
Figure 2. Modalities of metastasis. Metastasis is achieved by a step wise progression of tumor cell 
dissociation, physical translocation, and colonization. (a.) Cell dissociation entails a combination of 
cell–cell junctional complex rearrangements; phenotypic transitions, like EMT, that result in a loss of 
epithelial junctions; or the passive severance of cell clusters by virtue of forces exerted by the 
interstitial fluids. (b.i.) Physical translocation involves a myriad of processes, amongst which cell 
migration is mediated by individual or collective clusters of cells. Individual cells migrate with the 
aid of ECM or stroma derived nanotubes, whereas collective migration is achieved by an active 
leading edge and/or by migration of cell sheets. (b.ii.) Migrating cells then undergo intra- and 
trans-tissue invasion by mediating distinct interactions with the ECM and non-transformed cell 
populations. Intra-tissue invasion involves the degradation and deformation of the ECM, either by 
the tumor or stromal cells. Alternatively, cells exhibit amoeboid invasion by altering their membrane 
fluidity so as to squeeze through the ECM with minimal disturbance to the surrounding architecture. 
Figure 2. Modalities of metastasis. Metastasis is achieved by a step wise progression of tumor cell
dissociation, physical translocation, and colonization. (a.) Cell dissociation entails a combination of
cell–cell junc ional complex earrangements; phenotypic transitions, like EMT, that result in a loss of
epithelial junctions; or the passive severance of cell clusters by virtue f forces exerted by the interstitial
fluids. (b.i.)
J. Clin. Med. 2019, 8, 941 8 of 22
Physical translocation involves a myriad of processes, amongst which cell migration is mediated by
individual or collective clusters of cells. Individual cells migrate with the aid of ECM or stroma derived
nanotubes, whereas collective migration is achieved by an active leading edge and/or by migration
of cell sheets. (b.ii.) Migrating cells then undergo intra- and trans-tissue invasion by mediating
distinct interactions with the ECM and non-transformed cell populations. Intra-tissue invasion involves
the degradation and deformation of the ECM, either by the tumor or stromal cells. Alternatively,
cells exhibit amoeboid invasion by altering their membrane fluidity so as to squeeze through the ECM
with minimal disturbance to the surrounding architecture. (b.iii.) Trans-tissue invasion involves the
disruption of endothelial linings by virtue of active intra-/extra-vasation or mechanical rupture because
of an extensive tumor load. (b.iv.) Disseminating tumor cells in circulatory/lymphatic systems can exist
either as platelet or tumor associated macrophage (TAMs) coated entities, mesenchymal cells along
capillary linings, passively dispersed cell clusters, or exhibit an integrin mediated tumbling similar to
cells of the immune system. (c.) The final stage of metastases establishment involves the colonization of
tumor cells at distant sites mediated by phenotypic transitions, like mesenchymal to epithelial transition
(MET), the selective seeding of epithelial cells from heterogeneous clusters, paracrine transformation of
secondary site by the tumor cell secretome, passive deposition by interstitial fluids, and modulation of
the secondary niche by activation of the tissue stromal compartment.
While several assays depict the properties associated with cell dissemination, the direct detection
of metastatic seeding is not achieved in vitro. Metastasis-associated studies also disregard the
stages of intra-/extra-vasation and the associated cellular plasticity that may govern efficacy of the
metastatic cascade [102,103]. Importantly, routine in vivo models are usually limited by their inherent
immunodeficiency that impacts the heterogeneity and efficiency of metastatic dissemination [104].
Similarly, the ectopic transplantation of tumor cells in mice and the infiltration of mouse stroma in
these models make them less suitable for studying the role of tumor microenvironment on metastatic
dissemination [104]. Thus, despite the existence of numerous elegant model systems, the complexity
of metastasis necessitates regular improvements in assay resolution, and emphasizes the inclusion of
recent ideologies when inferring from these outputs.
3. Uncoupling the Migration–Invasion–Metastasis Ideology
Tumors hijack several molecular programs associated with organogenesis; hence, concepts derived
from developmental systems could elucidate the functional attributes observed during tumor
progression and metastasis. Apart from tumor cells, the recruitment of tissue stroma/immune
components vastly influences each stage of the metastatic cascade in a context dependent manner.
The exclusion of several physiological parameters from experimental systems may stem from the
limited familiarity and visualization of such processes, which can limit their collation with clinical
observations. In this section, we aim to highlight the alternate physiological mechanisms adopted by
tumors that uncouple the traditional migration–invasion–metastasis ideology, and warrant inclusion
in routine assays (Figure 2).
The dissociation of cells from the primary tumor is widely attributed to active EMT as well as
its molecular manifestations that affect cell adhesion and cytoskeletal complexes [105]; other studies
highlight the realignment of adhesion complexes towards the generation of passively disseminating
epithelial cell clusters [19]. Passive dissemination presents a challenge for experimental detection,
although its contribution to metastasis is undeniable (Figure 2a) [106,107]. The degradative secretome
that often accompanies EMT can further lead to the severance of single cells from the primary mass [96].
Tumors are also subject to hydrostatic pressures from organ-specific interstitial fluids that slough off
weakly connected proliferative cell masses. Separately, the tumor edge can undergo cytoskeleton
mediated delamination as epithelial sheets, a feature also noted during development [108].
Several existing studies associate metastatic efficacy with EMT facilitated migration and
invasion [109–111]. However, recent reports highlight the differential migratory and invasive
capabilities of tumor cells, significantly influenced by the microenvironment (Figure 2b.i).
Passively dissociated cells can disperse and seed as proximal metastatic lesions in the absence of active
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migration/invasion programs [106,112]. Furthermore, efficient cell migration along chemo-/duro-tactic
gradients relies on the sustained cellular contacts that underscore the existence of epithelial properties
and fortify collective migration as a crucial process in disseminating tumor cells [112]. Recent studies
also highlight the role of tumor/stroma cell derived membrane invaginations, termed “nanotubes” that
can alter ECM arrangement and serve as directed migratory tracks for cancer cells [113].
The uncoupling of EMT from the metastatic cascade is also evident from reports highlighting the
invasion of epithelial cell clusters by virtue of tensile forces exerted on the ECM (Figure 2b.ii) [114,115].
Invasion is also reported to be mediated by an amoeboid transition, which allows cells to squeeze
through the ECM, without its biochemical or mechanical alteration [98]. Invasion modalities can
be influenced by organ-specific architecture, which presents as an anatomical barrier for metastasis.
For example, fenestrated bone marrow sinusoids offer a lower mechanical challenge for invasion,
as opposed to the blood–brain barrier [116]. Distal metastasis is further ascertained by the density of
lymphatic/blood vessels, and the ability of tumor cells to intra- and extra-vasate; invasive cell clusters
capable of disrupting the basal lamina and entering circulation may stay lodged in the blood vessels
and fail to extravasate (Figure 2b.iii) [117]. Tumor cells in capillaries or lymphatic vessels ensure
survival in response to immune surveillance and hydrostatic pressures by existing as cell clusters or
recruiting cells from the hematopoietic lineage [2]. Eventually, cells achieve distant dissemination
under the influence of systemic circulatory flow, and can also exhibit migration along the capillary
linings by virtue of mesenchymal motility or integrin mediated tumbling (Figure 2b.iv) [118,119].
Several of the above phenomena are reversed during the colonization stage of metastasis,
wherein tumor cells re-establish cellular contacts and lodge into a supportive niche (Figure 2c).
The reversal of certain mesenchymal properties is thus deemed crucial for colonization, as reports
highlight the inability of rigid mesenchymal cells to metastasize, despite in vitro migratory and
invasive capabilities [34,120]. Phenotypic plasticity plays a key role in enhancing the adaptability
of cells to the altered niche, and may generate a heterogeneous disease at distinct sites in response
to varying microenvironments [121,122]. The passive deposition and selective seeding of epithelial
tumor cells from heterogeneous metastasizing clusters can dictate the efficacy of metastasis [106,
107,112]. Sculpting of the secondary site is also undertaken by tumor cells, wherein paracrine
signaling can result in a transformation of the secondary tissue or activate stromal cells, and generate
a microenvironment conducive to metastases seeding [100]. Insights into the role of these extra-tumoral
cellular components have been reviewed elsewhere [84,85]. Thus, a definitive comprehension of the
metastatic cascade necessitates an approach wherein the aforementioned processes can be integrated
into informative protocols.
4. Visualization of Metastatic Modalities with Real-Time Approaches
As discussed in previous sections, comprehending the biological heterogeneity of metastasis is often
limited by the poor resolution of snapshot assays. Existing assays can provide an enhanced resolution
of the cellular functionalities, when coupled with microfluidic approaches, real-time visualization,
and intra-vital imaging. These methods can further reform traditional ideologies by including
physiologically relevant variables and the development of quantitative parameters to delineate the
metastatic cascade (Figure 3).
J. Clin. Med. 2019, 8, 941 10 of 22
J. Clin. Med. 2019, 8, x FOR PEER REVIEW 10 of 22 
 
including physiologically relevant variables and the development of quantitative parameters to 
delineate the metastatic cascade (Figure 3). 
 
Figure 3. Era of real-time analysis. Routine implementation of real-time approaches in cancer biology 
can spatio-temporally resolve cellular processes and biological modalities by permitting the 
extraction of quantitative metrics associated with these states. Outputs from real-time studies can be 
collated to identify the regulatory networks governing the biological processes, and can be further 
applied to develop analytical tools/mathematical models for implementation in therapeutic/clinical 
screens. Such analyses support the design of relevant animal models, recapitulating the in situ 
patho-physiological parameters of the disease. Corroboration with microfluidic devices further 
enhances the outputs of these pipelines. 
4.1. Use of Microfluidics 
Microfluidic devices are recent advances in automation that have been applied in order to 
elucidate the distinct ECM components, widths of migratory paths, cell adhesion forces associated 
with collective migration, and the effect of extrinsic fluid pressures, amongst other metrics 
associated with metastasis [103,123–125]. In a recent study, an artificial circulatory system was 
generated on PDMS (polydimethylsiloxane) micro-capillaries lined with functional endothelial cells. 
This system was employed to model extra-/intra-vasation modalities under influences of extrinsic 
Figure 3. Era of real-time analysis. Routine implementation of real-time approaches in cancer
biology can spatio-temporally resolve cellular processes and biological modalities by permitting the
extraction of quantitative metrics associated with these states. Outputs from real-time studies can be
collated to identify the regulatory net orks governing the biological processes, and can be further
applied to develop analytical tools/ at e atical els for i plementation in therapeutic/clinical
screens. Such analyses s t t i f levant animal models, recapitulating the in situ
patho-physiological parameters of the dise Co roboration with microflu dic devices further
enhances the outputs of these pipelines.
4.1. Use of Microfluidics
Microfluidic devices are recent a vances in auto ation that have been applied in order to
elucidate the distinct ECM compone ts, widths of migratory paths, cell adhesion forces a sociated with
collective migration, and the effect of extrinsic fluid pressures, amongst other metrics associat d with
metastasis [103,123–125]. In a recent study, an rtificial circulatory system was generated on PDMS
(polydim thylsiloxane) micro-capillaries lined with functional endothelial cells. This system was
employed to model extra-/intra-vasation modalities under influences of extrinsic fluid pressure [102].
Label-free isolation and characterization of viable CTC clusters from blood samples has been achieved
with Cluster-Chip, a microchip technology employing bifurcation traps. CTCs released from the
microchip could be subjected to functional and molecular characterization in vitro, to comprehend
their role in the metastatic cascade [126]. Similarly, an organ chip bioengineered to mimic the 3D
microvascular networks has been effective in capturing and quantifying trans-endothelial migration,
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seeding, and micro-metastases formation [127]. Similar approaches have also used 3D bio-matrices to
generate tissue models for studies pertaining to the interaction and infiltration of cancer cells [128–130].
Recently, the co-culture of breast cancer cells and CAFs on a microfluidic device successfully established
a 3D-organotypic model to mimic stroma-driven tumor cell invasion. Live cell imaging coupled with
transcriptome analysis of the co-cultured cells further discerned the novel molecular targets associated
with invasion [131]. The recapitulation of spatio-temporal metabolic adaptations encountered by
tumor cells was also achieved with a microfluidic organotypic breast cancer model, and employed to
devise therapeutic strategies for targeting hypoxic cells [132].
4.2. In Vitro Resolution of Metastatic Modalities with Live Cell Imaging
Independent of microfluidic devices, live cell imaging has enabled the quantification of various
functional properties by visually monitoring routine in vitro protocols. The spontaneous detachment
of cells from 3D culture models of ovarian cancer was recently visualized with live cell imaging.
These observations allowed for the development of in vivo lineage tracing methods, and discerned
a collective dissociation of cells from the primary tumor, indicating the onset of metastasis [37]. A recent
study from our group, coupling live cell imaging with the in vitro scratch assay, not only discerned
the distinct migratory modalities in ovarian carcinoma (CCM versus EMT), but also resolved subtle
variations within CCM; this defined CCM as being mediated either through proliferation (passive
CCM) or sheet-like migration (active CCM). We quantified the altered migratory modalities in response
to extrinsic and intrinsic stimuli, further establishing an improved prototype of the scratch assay [99].
In a separate study, CCM was assessed in the context of durotaxis, wherein live cell imaging successfully
quantified the extent and pattern of migration in response to ECM variations [133]. Similar approaches
were applied to invasion assays, so as to determine the morphological variations of patient derived
spheroids invading into a carboxy–methyl cellulose matrix [134]. Separately, live cell imaging of
the migrating cells in a confined micro-pillar array permitted the derivation of distinct quantitative
parameters for distinguishing the individual and collective modes of migration [135].
Real-time studies can thus offer an improved comprehension of the bio-mechanical features
associated with metastasis that are often overlooked by snapshot assays (Table S3). The corroboration of
time-lapse microscopy with trans-well invasion assays could distinguish the degradative, deformative,
and amoeboid modes of cell invasion [98,136]. Similar approaches with co-culture systems can delineate
the proliferation driven disruption of endothelial linings from active events of intra-/extra-vasation,
and in suspension cultures, distinguish the mechanical forces associated with spheroids versus cellular
aggregates [38,115,137]. The assay resolution can be further enhanced by employing fluorescent dyes
or protein tags that differentially label cell membranes, ECM fibers, cytoskeletal components, and so
on. Importantly, the labelling methods adopted for real-time imaging studies must be permissive of
the assay systems, and contribute minimal hindrance to the biological process under study [138,139].
Such real-time analysis can also be implemented in high-throughput screens, along with traditional
assay outputs, so as to address the effects of growth additives and pharmacological compounds on
diverse biological modalities.
4.3. Intra-Vital Imaging Assisted Visualization of Cellular Properties
As discussed previously, the limited in vitro recapitulation of the heterogeneity associated with
metastasis has compelled cancer biologists to use animal models suitable for varied experimental
approaches. The in vivo dynamics of migration and invasion have been previously noted in C. elegans,
fruit fly, and zebrafish [67]. Recent advances in microscopy and fluorophore chemistry have also
permitted the intra-vital single-cell resolution in vertebrate animal models. In a mouse model,
intra-vital imaging assisted approaches elucidated the role of Rac1-dependent membrane protrusions
in the maintenance of 3D spatial positions of mouse dermal fibroblasts during wound healing [140].
In yet another report, the transplantation of tumor cells into the mouse cerebellopontine angle region
coupled with intra-vital imaging successfully developed a model to study the disease progression of
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vestibular schwannoma [141]. Separately, the intra-vital imaging of early breast carcinoma lesions
identified a Her2 driven dissemination program that enables the dispersal of dormant cancer cells
to distant organs, prior to the development of a primary tumor [142]. Intra-vital imaging also
successfully discerned the significance of orthotopic, as opposed to subcutaneous, tumor models
in prostate cancer wherein drastic differences in the overall vascularization and distant metastasis
were duly noted [143]. Intra-vital imaging has been aided by confetti mouse models, which express
a combination of fluorescent proteins in response to the Cre-recombinase, and permit the visualization
of the in vivo heterogeneity inherent to tissue systems [144,145]. Confetti mice have been instrumental
in comprehending squamous cell carcinoma progression, wherein the recruitment of the adjacent
epithelium by monoclonal papillomas and intra-tumoural invasion by newly generated clones
were effectively visualized [146]. Cell of origin studies in castration resistance prostate cancer,
employing confetti mice, have previously assigned tumor formation to a population of Bmi1+ve luminal
cells in the proximal prostate [83]. The in vivo fate and properties of transplanted corneal epithelium
were also resolved with intra-vital imaging, which tracked the fluorescence signals from the confetti
tagged donor cells [147].
Other advances in imaging technologies include improved tomography scans, fluorescence lifetime
imaging microscopy (FLIM), coherent anti-Stokes Raman microscopy (CARS), and so on, and have been
reviewed elsewhere in detail [148,149]. The routine application of such high-resolution approaches
may be beneficial towards the development of more informative protocols, the quantification of key
biomechanical features, and could overcome several limitations harbored by snapshot studies.
5. Quantitative Resolution of Biological Modalities
Examples of real-time assays discussed in previous sections not only emphasize their visual impact,
but also highlight the derivation of varied quantitative metrics. The integration of live cell imaging
into routine approaches can quantify diverse physiological parameters and enhance assay read-outs.
We briefly familiarize readers with recent approaches developed for high-resolution real-time imaging,
user-friendly analytical tools, and quantitative variables generated from imaging datasets (Table S3).
Continued technological advances and automation in the field of optics have provided
high-resolution microscopes that facilitate the real-time visualization of dynamic biological processes,
including the migration of metastatic cancer cells in vivo [150]. Similarly, atomic force microscopy
(AFM) and protrusion force microscopy (PFM) have been employed to discern the mechanical forces
involved in leukocyte–endothelial adhesion and invadosome–assisted extravasation, respectively [151].
CARS coupled with two-photon imaging has also emerged as a promising approach to describe
multiple aspects of the tumor niche and disease progression, with minimal photo-damage to the
specimen [73]. Interested readers may refer to several recent articles elaborating on the advances in
microscope design, with significant implications in real-time cancer research [148,149].
Datasets generated by real-time imaging present a significant challenge for analysis,
thus necessitating familiarity with relevant software and tools. While the adaptability of imaging
tools across model systems is beneficial, optimal quantification can only be ensured when
high-resolution/-contrast images are provided as inputs. The availability of user-friendly interfaces,
improvements with recent plugins, and the development of codes for the customization of outputs
enhance the applicability of imaging tools. Currently, a variety of programs facilitate time-lapse
image analysis, and are available either commercially, viz., Metamorph (Olympus), Imaris (Bitplane),
Zen (Zeiss), Elements (Nikon), Volocity (PerkinElmer), and so on, or as open source platforms,
viz., Micro-manager, ImageJ, MotilityLab, and so on. Imaris is specifically useful for 4D data
analysis, and can be substituted with the ImageJ post-installation of plugins that facilitate drift
correction, volume measurement, free rotation, and so on [152]. COMBImage, a recent computational
framework, has facilitated the automated analyses of cell morphology and confluence in cell viability
assays [153]. The management and analysis of multi-dimensional imaging data have also been aided
by support vector machines (SVM), which have been applied to group pixels for image segmentation,
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to detect cellular/sub-cellular phenotypes, or to categorize developmental stages at the level of
entire organisms [154]. Similarly, mathematical approaches for migration track analysis have been
developed [155]. A more comprehensive list of the currently available image processing software and
tools is available elsewhere [156,157].
Analytical tools can yield extensive information from imaging datasets, and often confound
untrained individuals. The extraction of relevant quantitative metrics must consider the biophysical
properties of a system and examine the associative trends with the cellular processes under study.
Examples highlighting the selection of quantitative metrics are summarized in Table S3, and include
the micro-pillar array-based study, wherein six quantitative parameters extracted from individual
cells generated a binary solidification model for describing the interconversion between collective
versus individual modes of migration [135], fractal analysis that described the developing dermis
as a lattice structure resulting from the dynamic stroma [158], derivation of migration modalities in
ovarian cancer cell lines assisted by coupling live cell imaging with the in vitro scratch assay [99],
and so on. Additional studies highlight the vast array of quantitative measures derived from real-time
imaging datasets, and signify their contributions to an improved understanding of the biological
processes [11,151,159–162].
6. The Era of Live Cell Imaging
The simple corroboration of time-lapse microscopy with endpoint assays can reveal the modalities
of several biological processes, indicate differential routes of metastasis taken by tumors, and identify
the associated molecular pathways (Figure 3). Collation of these datasets can generate multi-parametric
simulations that define the biological thresholds associated with diverse cellular functions, and their
modulation in response to various cues [163–165]. Such models or simulations could aid in the
design of appropriate experimental systems that encompass heterogeneous processes contributing to
metastasis. Similarly, analytical tools developed with real-time approaches can be integrated into drug
development pipelines [166]. In accordance with our statements, a recent study employing intra-vital
imaging discerned the crucial role of CD44 driven cell aggregation of CTCs in metastatic dissemination.
The study established CD44–PAK2 interaction as a driving event of the process, thus providing clinically
relevant information with the aid of visual outputs [167]. While snap-shot assays will continue to
provide high-throughput readouts for cell systems, it is crucial that experimentalists acknowledge
their limitations when deriving clinically relevant inferences. With the right amount of caution,
real-time approaches could herald an “era of live cell imaging” in cancer biology.
Real-time approaches, in conjunction with lineage tracing, may initiate the next phase of resolving
cancer heterogeneity, which continues to elude comprehension and is responsible for therapy resistance.
In view of recent reports, real-time approaches may decipher functional nuances and provide insight into
the concept of “metastability” predicted during phenotypic switches. Real-time dynamics of molecular
turn-over can further identify the spatiotemporal alterations of markers over the course of disease
progression, and improve clinical interventions. Moreover, intra-vital imaging approaches present
an exciting opportunity to tackle a residual minimal disease, which often results in an aggressive
relapse and overall poor prognosis. Similarly, extra-tumoral cell populations crucial for disease
progression in vivo can be identified and probed in vitro with micro-fluidic and real-time studies.
More importantly, the stages of primary dissociation and colonization during metastasis represent
a “grey area” of information, which could be effectively resolved with the previously discussed
approaches. The delineation of these diverse biophysical features essentially nurtures the model of
personalized medicine. A careful combination of appropriate existing assays with live cell imaging can
reveal several nuances of the metastatic cascade and reiterate the “seeing is believing” ideology.
7. Conclusions
Recent studies reveal a functional uncoupling of several physiological processes previously
deemed crucial for successful metastasis. Our own observations associated with the evaluation of
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in vitro metastasis reflect on the shortcomings of routine assays. For the detection of distinct modalities
associated across the metastatic cascade, we suggest the adoption of time lapse imaging in routine
assays. This approach has the capability to (i) make a visual impact on biological processes, (ii) identify
different routes undertaken by tumor cells towards achieving these functions, and (iii) provide metrics
for quantifying these processes. The information obtained from these approaches can be applied
towards establishing mathematical models and intuitive inferences that tackle the heterogeneity
associated with disease progression. Inherent cellular plasticity that contributes to tissue homeostasis
can also be deciphered in the context of pathological conditions, by developing novel assays that
combine the ease of traditional approaches with the enhanced resolution of real-time imaging. We also
emphasize on the routine re-evaluation of functional read-outs, so as to incorporate recent conceptual
developments that improve the comprehension of biological systems. Together, these features are likely
to be useful in elucidating the poorly understood areas of disease progression in cancer, and deriving
clinically relevant conclusions over the current assays.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/7/941/s1:
Table S1. Metastasis associated functional read-outs. Details pertaining to the setup, quantification, and biological
read-out associated with the in vitro and in vivo methods employed to study the metastatic cascade are enlisted.
Table S2. Applications and limitations of metastasis associated functional read-outs. Details pertaining to
the cellular functionality gauged, stage of metastasis represented, and inherent limitations of the in vitro and
in vivo methods employed to study the metastatic cascade are enlisted. Table S3. The real-time approach.
Details pertaining to the model systems, relevant instrumentation, quantitative tools and variables, and their
biological relevance for recent real-time studies are enlisted. The table includes a summary of a limited number of
studies, interested readers may refer to the available literature cited in the text for more information.
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